Breaking News Instant updates and real-time market news.

REGN

Regeneron

$355.44

2.81 (0.80%)

, SNY

Sanofi

$44.78

0.65 (1.47%)

05:17
11/06/18
11/06
05:17
11/06/18
05:17

Regeneron, Sanofi granted FDA Priority Review for Dupixent sBLA

Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) announced that the FDA has accepted for Priority Review the supplemental Biologics License Application, or sBLA, for Dupixent in adolescent patients 12 to 17 years of age with moderate-to-severe atopic dermatitis, whose disease was inadequately controlled with topical therapies or for whom topical treatment was medically inadvisable. Currently, there are no FDA-approved systemic biologic medicines to treat adolescents with moderate-to-severe atopic dermatitis. The target action date for the FDA decision is March 11, 2019.

REGN

Regeneron

$355.44

2.81 (0.80%)

SNY

Sanofi

$44.78

0.65 (1.47%)

  • 06

    Nov

  • 27

    Nov

  • 28

    Jan

  • 22

    Mar

  • 28

    Apr

  • 13

    May

REGN Regeneron
$355.44

2.81 (0.80%)

10/17/18
JEFF
10/17/18
NO CHANGE
Target $31
JEFF
Buy
Jefferies still sees 'major' opportunity for Optinose after Dupixent data
Optinose (OPTN) shares underperformed yesterday following the positive Phase 3 results for Sanofi (SNY) and Regeneron's (REGN) Dupixent in treating patients with chronic rhinosinusitis with nasal polyps, Jefferies analyst David Steinberg tells investors in a research note titled "Biologics Competitor as Expected; Real World Pricing Issues Likely to Limit Us." The analyst says that while Dupixent demonstrated strong efficacy, clinicians he's spoken with believe that the "massive" pricing disparity versus nasal steroids will likely result in payer "step edits" that could limit widespread adoption of the "expensive" biologics currently under development. Further, Dupixent's head-to-head comparison with Optinose's Xhance's "strong" efficacy profile is difficult, the analyst adds. Steinberg still sees a "major" long-term opportunity for Xhance and keeps a Buy rating on Optinose with a $31 price target.
10/22/18
PIPR
10/22/18
NO CHANGE
Target $450
PIPR
Overweight
Regeneron asthma label for Dupixent broad as hoped, says Piper Jaffray
Piper Jaffray analyst Christopher Raymond says that while Regeneron Pharmaceuticals' asthma label for Dupixent does not broadly cover patients regardless of eosinophilic phenotype as he had anticipated, it does cover oral corticosteroid dependent patients regardless of eosinophilic phenotype, which essentially matches his modeling. Moreover, the analyst notes that the label covers all patients 12 and older, and both moderate and severe disease. As such, he sees the label as broad, "but not necessarily as anticipated." The analyst is making no change to his numbers based on the label and keeps an Overweight rating on Regeneron with a $450 price target.
10/22/18
CANT
10/22/18
NO CHANGE
Target $441
CANT
Neutral
Regeneron price target raised to $441 from $419 at Cantor Fitzgerald
Cantor Fitzgerald analyst Alethia Young raised her price target for Regeneron Pharmaceuticals to $441 citing Dupixent's label in asthma, which she thinks is broad. The analyst believes the shares could trade up 5% on the label but she keeps a Neutral rating on the name. Dupixent expectations are high already, Young tells investors in a research note.
10/29/18
MSCO
10/29/18
NO CHANGE
MSCO
Equal Weight
Morgan Stanley sees little impact to Regeneron from competitor data at AAO
Morgan Stanley analyst Matthew Harrison noted that data was presented at the American Academy of Ophthalmology's annual meeting for three potential competitors to Regeneron's (REGN) Eylea - Allergan's (AGN) abicipar pegol, Novartis' (NVS) brolucizumab and Roche's (RHHBY) faricimab. Following the presentations, his view on abicipar and brolucizumab is unchanged and he awaits further late-stage data from faricimab, said Harrison, who sees little impact to Regeneron based on the new data. He maintains an Equal Weight rating on Regeneron shares.
SNY Sanofi
$44.78

0.65 (1.47%)

10/23/18
WOLF
10/23/18
INITIATION
WOLF
Peer Perform
Sanofi reinitiated with a Peer Perform at Wolfe Research
10/25/18
WELS
10/25/18
NO CHANGE
WELS
Wells Fargo says Trump speech today won't be end of drug pricing proposals
Wells Fargo analyst David Maris notes that Politico and other media outlets are reporting that President Donald Trump will propose several new initiatives to address high drug prices when he speaks later today at the U.S. Department of Health and Human Services. Maris thinks Trump's focus will be on how other countries are "freeloading" on U.S. innovation with lower negotiated pricing, stating that news reports make it appear that the administration is targeting the industry for action, rather than other countries to raise their spending. While Maris acknowledges the timing of the speech being near the mid-term elections, he believes these proposals are simply the follow-though of earlier promises. He also expects this is not the end of proposals to address the issue of U.S. drug pricing. Publicly traded large-cap drugmakers include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY).
11/01/18
LEHM
11/01/18
UPGRADE
LEHM
Equal Weight
Sanofi upgraded to Equal Weight from Underweight at Barclays
Barclays analyst Emmanuel Papadakis upgraded Sanofi to Equal Weight and raised his price target for the shares to EUR 80 from EUR 68 following the company's Q3 results. The analyst sees a more balanced risk/reward profile at current share levels.
11/01/18
11/01/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Nutrisystem (NTRI) upgraded to Outperform from Market Perform at Barrington and to Neutral from Underperform at DA Davidson. 2. SeaWorld (SEAS) upgraded to Overweight from Sector Weight at KeyBanc with analyst Brett Andress saying de-risked expectations following the Q3 pre-announcement create an attractive entry point, as he sees further upside to shares, with his confidence in the company's turnaround bolstered by additional evidence of both a brand and business in recovery mode. 3. Sanofi (SNY) upgraded to Equal Weight from Underweight at Barclays with analyst Emmanuel Papadakis saying he sees a more balanced risk/reward profile at current share levels. 4. Asur (ASR) upgraded to Overweight from Neutral at JPMorgan with analyst Fernando Abdalla citing valuation. 5. Wex (WEX) upgraded to Outperform from Market Perform at Wells Fargo. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

TODAY'S FREE FLY STORIES

BE

Bloom Energy

$16.04

0.56 (3.62%)

08:08
11/19/18
11/19
08:08
11/19/18
08:08
Hot Stocks
Bloom Energy enters strategic partnership with SK E&C »

SK Group and Bloom Energy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

DRRX

Durect

$0.91

-0.0094 (-1.02%)

08:07
11/19/18
11/19
08:07
11/19/18
08:07
Hot Stocks
Durect amends ongoing Phase 2a trial of DUR-928 »

Durect announced it has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CACI

CACI

$180.35

-0.03 (-0.02%)

08:07
11/19/18
11/19
08:07
11/19/18
08:07
Hot Stocks
CACI awarded $413M contract for U.S. Army communications systems support »

CACI International…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TLND

Talend

$37.44

-1.13 (-2.93%)

08:07
11/19/18
11/19
08:07
11/19/18
08:07
Recommendations
Talend analyst commentary  »

Talend price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

  • 06

    Dec

MGTA

Magenta Therapeutics

$7.50

0.4 (5.63%)

08:06
11/19/18
11/19
08:06
11/19/18
08:06
Hot Stocks
Magenta Therapeutics names Jason Ryan as Chief Operating and Financial Officer »

Magenta Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Dec

NERV

Minerva

$8.41

0.11 (1.33%)

08:06
11/19/18
11/19
08:06
11/19/18
08:06
Hot Stocks
Minerva announces results from roluperidone study »

Minerva announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

BKI

Black Knight

$49.77

0.87 (1.78%)

, DNB

Dun & Bradstreet

$142.27

0.11 (0.08%)

08:05
11/19/18
11/19
08:05
11/19/18
08:05
Hot Stocks
Black Knight board approves $375M investment in Dun & Bradstreet »

Black Knight (BKI)…

BKI

Black Knight

$49.77

0.87 (1.78%)

DNB

Dun & Bradstreet

$142.27

0.11 (0.08%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

  • 03

    Dec

CMP

Compass Minerals

$52.49

0.98 (1.90%)

08:04
11/19/18
11/19
08:04
11/19/18
08:04
Hot Stocks
Compass Minerals CEO to step down, Dick Grant named interim CEO »

Compass Minerals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LANC

Lancaster Colony

$182.53

-0.21 (-0.11%)

08:03
11/19/18
11/19
08:03
11/19/18
08:03
Hot Stocks
Lancaster Colony acquires assets of Omni Baking Company for $25M »

Lancaster Colony…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TENX

Tenax Therapeutics

$3.80

(0.00%)

08:03
11/19/18
11/19
08:03
11/19/18
08:03
Hot Stocks
Tenax activates first clinical research site for Phase 2 trial of levosimendan »

Tenax Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SLDB

Solid Biosciences

$33.82

2.81 (9.06%)

, SRPT

Sarepta

$119.02

0.14 (0.12%)

08:02
11/19/18
11/19
08:02
11/19/18
08:02
Conference/Events
Morgan Stanley to hold a bus trip »

Biotech Boston Bus Trip…

SLDB

Solid Biosciences

$33.82

2.81 (9.06%)

SRPT

Sarepta

$119.02

0.14 (0.12%)

NTGN

Neon Therapeutics

$6.98

-0.1 (-1.41%)

EDIT

Editas Medicine

$29.00

0.92 (3.28%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

NEE

NextEra Energy

$180.41

1.27 (0.71%)

08:02
11/19/18
11/19
08:02
11/19/18
08:02
Hot Stocks
NextEra Energy Transmission to acquire Trans Bay Cable for approximately $1B »

NextEra Energy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

KMB

Kimberly-Clark

$111.22

0.43 (0.39%)

08:01
11/19/18
11/19
08:01
11/19/18
08:01
Periodicals
Kimberly-Clark won't sell European tissue business with bids too low, FT says »

Kimberly-Clark will call…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

08:01
11/19/18
11/19
08:01
11/19/18
08:01
Conference/Events
Bernstein to hold a symposium »

5th Annual Asset…

NEE

NextEra Energy

$180.41

1.27 (0.71%)

08:01
11/19/18
11/19
08:01
11/19/18
08:01
Hot Stocks
Breaking Hot Stocks news story on NextEra Energy »

NextEra Energy to acquire…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

08:01
11/19/18
11/19
08:01
11/19/18
08:01
Conference/Events
Wedbush to hold a tour »

2018 Holiday Shopping…

HP

Helmerich & Payne

$62.59

2.54 (4.23%)

08:00
11/19/18
11/19
08:00
11/19/18
08:00
Upgrade
Helmerich & Payne rating change  »

Helmerich & Payne…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SASR

Sandy Spring Bancorp

07:57
11/19/18
11/19
07:57
11/19/18
07:57
Upgrade
Sandy Spring Bancorp rating change  »

Sandy Spring Bancorp…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SBH

Sally Beauty

$20.61

-0.425 (-2.02%)

07:57
11/19/18
11/19
07:57
11/19/18
07:57
Recommendations
Sally Beauty analyst commentary  »

Sally Beauty price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NHLD

National Holdings Corp

$2.96

(0.00%)

07:57
11/19/18
11/19
07:57
11/19/18
07:57
Hot Stocks
Breaking Hot Stocks news story on National Holdings Corp »

National Holdings Corp…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

QIWI

Qiwi

$14.15

-0.28 (-1.94%)

07:55
11/19/18
11/19
07:55
11/19/18
07:55
Conference/Events
Qiwi to host investor day »

Investor Day to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

MDGL

Madrigal Pharmaceuticals

$129.47

-3.36 (-2.53%)

07:54
11/19/18
11/19
07:54
11/19/18
07:54
Recommendations
Madrigal Pharmaceuticals analyst commentary  »

Madrigal Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

BAX

Baxter

$66.49

0.68 (1.03%)

07:54
11/19/18
11/19
07:54
11/19/18
07:54
Recommendations
Baxter analyst commentary  »

Baxter confident in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Dec

  • 05

    Dec

LONE

Lonestar Resources

$7.03

-0.32 (-4.35%)

07:52
11/19/18
11/19
07:52
11/19/18
07:52
Hot Stocks
Lonestar Resources announces Eagle Ford shale acquisition »

Lonestar Resources…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Nov

GOOGL

Alphabet Class A

$1,069.13

-2.09 (-0.20%)

, GOOG

Alphabet

$1,062.01

-2.73 (-0.26%)

07:52
11/19/18
11/19
07:52
11/19/18
07:52
Recommendations
Alphabet Class A, Alphabet, Oracle analyst commentary  »

JMP says former Oracle…

GOOGL

Alphabet Class A

$1,069.13

-2.09 (-0.20%)

GOOG

Alphabet

$1,062.01

-2.73 (-0.26%)

ORCL

Oracle

$51.19

0.55 (1.09%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

  • 05

    Dec

  • 06

    Dec

  • 03

    Mar

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.